Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
暂无分享,去创建一个
M. Konopleva | H. Kantarjian | J. Cortes | A. Quintás-Cardama | S. Verstovsek | T. Kadia | E. Jabbour | N. Daver | S. Pierce | S. O'brien | A. Shastri | Lingsha Zhou | A. Quintás-Cardama
[1] H. Kantarjian,et al. A Phase II Study of Low-Dose Pomalidomide (0.5mg/day) and Prednisone Combination Therapy in Patients with Myelofibrosis and Significant Anemia , 2012 .
[2] K. Döhner,et al. Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364). , 2012 .
[3] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[4] R. Mesa,et al. Long‐term outcome of pomalidomide therapy in myelofibrosis , 2012, American journal of hematology.
[5] A. Tefferi,et al. Circulating levels of MCP‐1, sIL‐2R, IL‐15, and IL‐8 predict anemia response to pomalidomide therapy in myelofibrosis , 2011, American journal of hematology.
[6] F. Passamonti,et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Barbui,et al. What are RBC-transfusion-dependence and -independence? , 2011, Leukemia research.
[8] R. Mesa,et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis , 2011, Leukemia.
[9] Ayalew Tefferi,et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.
[10] M. Cazzola,et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.
[11] R. Mesa,et al. Phase1/‐2 study of Pomalidomide in myelofibrosis , 2010, American journal of hematology.
[12] H. Kantarjian,et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Linch,et al. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. , 2009, Blood.
[14] H. Deeg,et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Tefferi,et al. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion‐dependent patients with primary myelofibrosis regardless of serum erythropoietin level , 2009, European journal of haematology.
[16] A. Green,et al. Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones , 2009, British journal of haematology.
[17] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.
[18] A. Dalgleish,et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells , 2009, Cancer Immunology, Immunotherapy.
[19] D. Verhelle,et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. , 2008, Journal of Clinical Investigation.
[20] A. Pardanani. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials , 2008, Leukemia.
[21] D. Verhelle,et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. , 2007, Cancer research.
[22] J. Sloan,et al. The Burden of Fatigue and Quality of Life in Myeloproliferative Disorders (MPDs): An International Internet Based Survey of 1179 MPD Patients. , 2006 .
[23] P. Greenberg,et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.
[24] H. Deeg,et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). , 2006, Blood.
[25] H. Kantarjian,et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. , 2006, Blood.
[26] H. Kantarjian,et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia , 2006, Cancer.
[27] J. Rossi,et al. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. , 2006, Haematologica.
[28] A. Tefferi. Pathogenesis of myelofibrosis with myeloid metaplasia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Hoffman,et al. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. , 2005, Blood.
[30] E. Montserrat,et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long‐term results in 30 patients , 2005, British journal of haematology.
[31] A. Dalgleish,et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Angus G. Dalgleish,et al. The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.
[33] P. Musto. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. , 2004, Leukemia research.
[34] M. Le Bousse-Kerdilès,et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Steensma,et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. , 2003, Blood.
[36] A. Dalgleish,et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects , 2002, British Journal of Cancer.
[37] G. Barosi,et al. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia , 2001, British journal of haematology.
[38] F. Wendling,et al. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. , 2000, Blood.
[39] P. Haslett,et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.